Future Market Insights (FMI) predicts that between 2020 and 2030, the worldwide allergy immunotherapy market will grow at a healthy rate. According to the estimate, by the end of 2030, the market will be worth US$ 2,892.2 million.
The rising prevalence of allergies such as allergic rhinitis, allergic asthma, food allergies, skin allergies, and other types of allergies is driving up the need for efficient therapies. As patients seek innovative treatments to build allergy resistance and live a life free of discomfort, allergy immunotherapy has emerged as a viable medical option. Future Market Insights (FMI) predicts that between 2020 and 2030, the worldwide allergy immunotherapy market will grow at a healthy rate. According to the report, the market will be valued at US$ 2,892.2 Mn by the end of 2030
Furthermore, allergic rhinitis is one of the most common allergens, affecting 10% to 30% of the world’s population. When a person is exposed to allergens – usually dust mites and pollen – it causes inflammation in the nose, swelling in the eyes, and sneezing, among other symptoms even though
Even though a significant section of the population does not seek medical help, greater awareness of the treatments available, combined with increased healthcare spending, is projected to be a key demand-side trend over the forecast period.
Key players:
- ALK Abello
- Stallergenes Greer
- Allergy Therapeutics
- Aimmune Therapeutics
- Energies
- Arrayit Corporation
- Biomay AG
- HAL Allergy Group
- DVB Technologies
For more insights into the market, Request a Sample Copy
